SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community anticipates potential volatility amid government shutdown concerns, often viewed as a bullish catalyst due to its decentralized nature. The cryptocurrency's potential as a safe haven asset and the start of 'Uptober' are also fueling positive sentiment. Community members are closely watching key resistance levels, anticipating a possible breakout.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as a cryptocurrency merging blockchain with cannabis culture, sparking interest in its potential for growth and innovation. Community members are actively sharing contract addresses and celebrating the coin's unique identity. The coin is presented as more than just a currency, but a movement towards freedom and cultural expression within the digital space.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market anticipates potential gains in the coming month, with some eyeing historical performance trends and others pointing to technical indicators suggesting a possible rally. Community members are actively debating potential price movements and key levels to watch, while also considering the impact of broader market factors. Some are discussing the influence of major financial institutions entering the crypto space.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community discusses potential catalysts for a price surge in October, including speculation around ETF approvals and the impact of a possible government shutdown. Some traders are weighing short-term bearish possibilities against the longer term outlook. Community members are also analyzing XRP's relationship with broader crypto market trends and developments with SWIFT.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the government shutdown looms, sparking debate about its potential impact on the market. While some traders anticipate a dip, drawing parallels to past shutdowns that saw gains, others believe current high valuations make this situation different. The community is weighing the potential for market volatility against historical trends, with some eyeing safe-haven assets.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as Elon Musk and others are reportedly canceling subscriptions due to concerns about the platform's content, sparking community debate about potential impacts.  While some anticipate a resulting dip, others dismiss the cancellations as insignificant, pointing to Netflix's large subscriber base.  The broader discussion involves content strategy and potential market effects in the competitive streaming landscape.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to its agreement with the Trump administration to lower drug prices via a new platform, coupled with a $70 billion investment in R&D and U.S. manufacturing. The community is weighing the potential impact on profit margins against the benefits of tariff exemptions and increased government favor. Some investors are also focusing on the company's acquisition of Metsera and its potential in the weight-loss drug market.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy ($MSTR) is trending as the community discusses its correlation to Bitcoin's price movements and potential for future growth, with some highlighting Michael Saylor's continued influence and the company's large Bitcoin holdings. Recent market activity has sparked debates about potential short squeezes and whether the stock is currently overvalued or undervalued relative to its net asset value (NAV). Discussions also involve potential government actions affecting crypto and their impact on $MSTR.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly ($DPRO) is trending due to increased community interest and positive sentiment around its potential in the drone and AI/IoT sectors, particularly following news of a US Army deal. Traders are actively discussing the stock's low float and potential for a short squeeze, with many anticipating significant upside and contract details to drive the price higher. Some see it as undervalued compared to other drone companies, like $RCAT and $ONDS.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending amid positive sentiment around Ethereum, with the community anticipating a potential rally and discussing the company's growing ETH holdings. Talk of a government shutdown and its potential impact on crypto is circulating, with some expecting BMNR to benefit. Technical analysis and predictions of significant price increases are also contributing to the heightened interest.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR  (ONC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?

Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Surges 4.0%: Is This an Indication of Further Gains?

BeOne Medicines Ltd. - Sponsored ADR  (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Summit Therapeutics Inc. (SMMT) surged more than 21% on Wednesday and extended gains in after-hours trading, driven by encouraging results from a late-stage cancer drug trial.The company’s sponsor, Akeso, announced that a phase 3 trial evaluating Summit’s drug, ivonescimab, in combination with chemotherapy, met its primary endpoint of progression-free survival in patients with advanced squamous non-small cell lung cancer (NSCLC).Akeso conducted the study across multiple centers in China, comparing the combination against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.An independent data monitoring committee found that the ivonescimab arm demonstrated statistically significant and clinically meaningful improvement.Summit plans to present the full dataset from the trial at a major medical conference later this year.&nbsp;On Stocktwits, sentiment for Summit rose further within 'extremely bullish' levels amid a 507% spike in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SMMT_sentiment_and_message_volume_as_of_April_23_png_a70ccf1959.webp" alt="SMMT sentiment and message volume as of April 23.png" width="1318" height="316"><figcaption>SMMT sentiment and message volume as of April 23. | source: Stocktwits</figcaption></figure>One bullish watcher urged investors to watch out for a "short squeeze up to $40."<stembedurl>https://stocktwits.com/BooEmmy/message/612403946</stembedurl>"The path is rising. And the journey has only just begun," said another.<stembedurl>https://stocktwits.com/Teluride/message/612467520</stembedurl>Summit is enrolling patients in a separate multiregional study pitting the same combination against pembrolizumab (Merck's Keytruda) plus chemo in first-line metastatic NSCLC. Early trial results from China have already shown promising results.The company also boosted investor enthusiasm after joining a clinical trial&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smmt-retail-chatter-explodes-on-pfizer-trial-pact/chdEqVTRx8">collaboration</a> with Pfizer in February.Summit's stock has surged by over 84% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Equity

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.


BeiGene to Present at Upcoming Investor Conferences

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside...

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial...

<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio shares</a> surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks&nbsp;while lifting retail sentiment.The clinical-stage immunotherapy company announced a collaboration and supply agreement with BeiGene to conduct a confirmatory Phase 3 clinical trial.&nbsp;The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for patients with advanced or metastatic non-small cell lung cancer who have developed resistance to immune checkpoint inhibitor therapy.According to ImmunityBio, multiple Phase 1 and 2 studies have already shown prolonged overall survival with this combination compared to historical chemotherapy results in similar patients.&nbsp;The upcoming Phase 3 trial, conducted globally across multiple sites, will enroll 462 participants. The primary endpoint is overall survival, while secondary measures include disease control rate, progression-free survival, objective response rate, and safety.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Jan_29_015db24b68.png" alt="IBRX sentiment and message volume Jan 29.png" width="1318" height="324"><figcaption>IBRX sentiment and message volume Jan 29 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘bullish’ for ImmunityBio on Wednesday, up from ‘neutral’ a day ago, while BeiGene’s sentiment shifted to ‘extremely bullish’ amid a spike in message volume.&nbsp;One user speculated that BeiGene could also become ImmunityBio’s global partner for bladder cancer treatments, suggesting another announcement might follow soon.&nbsp;<stembedurl>https://stocktwits.com/Dmck9/message/601987411</stembedurl>Another post predicted a 150% rally in the coming weeks.<stembedurl>https://stocktwits.com/Terrashae/message/601984996</stembedurl>ImmunityBio has been a closely watched stock among retail traders, with its Stocktwits following growing by nearly 43% in the past year despite a 10% decline in the stock’s price over the same period.&nbsp;Year to date, however, shares are up nearly 28%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as...

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

BeOne Medicines Ltd - ADR

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

ONC
BeiGene Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ONC News

ONC BeiGene Ltd - ADR